Angion Provides Corporate Update and Reports Full Year 2021 Financial Results
30 mars 2022 16h05 HE
|
Angion Biomedica Corp.
-- Enrollment continues in Phase 2 JUNIPER trial of ANG-3070 for the treatment of patients with primary proteinuric kidney diseases -- Ended the year with nearly $89M in cash and cash equivalents ...
Angion Announces Participation in Upcoming Investment Conferences
28 févr. 2022 16h05 HE
|
Angion Biomedica Corp.
UNIONDALE, N.Y., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a biopharmaceutical company focused on the discovery, development, and commercialization of novel small...
Angion Provides Corporate Update and Announces Participation in Upcoming Investor Conference
04 janv. 2022 16h05 HE
|
Angion Biomedica Corp.
-- First patient enrolled in the Phase 2 trial of ANG-3070 in primary proteinuric kidney diseases -- Angion will end 2021 with approximately $88.8 million in cash and cash equivalents UNIONDALE,...
Angion Provides Corporate Update and Reports Third Quarter 2021 Financial Results
12 nov. 2021 07h00 HE
|
Angion Biomedica Corp.
UNIONDALE, N.Y., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel...
Corbus Pharmaceuticals Provides Management Team Updates
28 mars 2019 08h05 HE
|
Corbus Pharmaceuticals Holdings, Inc.
Mark Tepper, Ph.D., transitions to role of external Senior Scientific Advisor Robert Discordia, Ph.D., role expanded to lead Chemistry, Manufacturing and Controls operationsSergei Atamas, M.D.,...
FibroGen Announces Publication of Phase 2 Study Results Supporting the Potential of FG-3019 to Treat Patients With Idiopathic Pulmonary Fibrosis
11 mars 2016 08h00 HE
|
FibroGen, Inc.
SAN FRANCISCO, March 11, 2016 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) (FibroGen) announced today that the European Respiratory Journal (“ERJ”) published on-line a manuscript...